Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment Relapsed/Refractory Multiple Myeloma Patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Pharmacodynamics
- 08 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 May 2018.
- 08 Jan 2018 Planned primary completion date changed from 1 Mar 2018 to 1 May 2018.
- 08 Jan 2018 Status changed from recruiting to active, no longer recruiting.